Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A
Ling Liu,1 Jirong Lu,1 Barrett W Allan,2 Ying Tang,2 Jonathan Tetreault,1 Chi-kin Chow,1 Barbra Barmettler,2 James Nelson,2 Holly Bina,1 Lihua Huang,3 Victor J Wroblewski,4 Kristine Kikly1 1Biotechnology Discovery Research, Indianapolis, IN, 2Applied Molecular Evolution, Lilly Biotechnology...
Guardado en:
Autores principales: | Liu L, Lu J, Allan BW, Tang Y, Tetreault J, Chow C, Barmettler B, Nelson J, Bina H, Huang L, Wroblewski VJ, Kikly K |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5e331cf6122443a39273d7248c25dc03 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
por: Sekhon S, et al.
Publicado: (2017) -
Generalized tinea versicolor following initiation of ixekizumab therapy
por: Haroon Sayed Alam, BS, et al.
Publicado: (2021) -
Targeting IL-23 in psoriasis: current perspectives
por: Fotiadou C, et al.
Publicado: (2018) -
Secukinumab in the treatment of psoriasis: patient selection and perspectives
por: Yang EJ, et al.
Publicado: (2018) -
Generation and Characterization of Torudokimab (LY3375880): A Monoclonal Antibody That Neutralizes Interleukin-33
por: Okragly AJ, et al.
Publicado: (2021)